NVS
Novartis AG ADR
NYSE: NVS · HEALTHCARE · DRUG MANUFACTURERS - GENERAL
$153.07
-0.55% today
Updated 2026-06-12
Market cap
$273.77B
P/E ratio
20.59
P/S ratio
4.84x
EPS (TTM)
$6.97
Dividend yield
3.30%
52W range
$109 – $165
Volume
1.5M
Novartis AG ADR (NVS) Financial Forecast & Price Target 2030
Research-backed projections from analyst consensus, management guidance, and sector analysis.
Research-backed NVS price target 2030 projection accounting for share dilution, balance sheet debt, and time value of money.
Current price
$153.07
Today
Analyst consensus
$141.20
-7.75% · 12M
2030 Base
$134.24
-12.30% future
NPV today
$97.43
@ 7% WACC
16 analysts:
7 Buy7 Hold2 Sell
Management guidance
Novartis has reaffirmed full-year 2026 guidance and provided sales guidance for 2025-2030, indicating confidence in current portfolio. CEO emphasized focus on innovative medicines, US expansion (with $23B investment in domestic manufacturing), and pipeline strength in oncology, immunology, and rare diseases. Management targets sustained mid-single-digit to low-double-digit revenue growth through 2030, though specific numerical targets were not disclosed in available guidance.
Sources: Management guidance, analyst consensus, sector analysishigh confidence
NVS · Novartis AG ADR · Revenue & price projection · 2023–2030E
Actual / 2030 target Projected revenue Base case price Bull to bear range
Bear case (2030)
$50.00
NPV today: $36.29
Base case (2030)
$134.24
NPV today: $97.43
Bull case (2030)
$218.48
NPV today: $158.57
WallStSmart.com
NVS financial forecast · Research-backed projections
| Metric | 2025 | 2026 (E) | 2027 (E) | 2028 (E) | 2029 (E) | 2030 (E) ★ |
|---|---|---|---|---|---|---|
| Revenue | $54.8B | $59.2B | $63.1B | $68.5B | $74.8B | $81.5B |
| Revenue growth | 6.0% | 4.5% | 6.6% | 8.5% | 9.2% | 8.9% |
| Net margin | — | 31.8% | 33.3% | 34.6% | 35.8% | 36.8% |
| EPS | $8.98 | $9.85 | $10.95 | $12.30 | $13.85 | $15.50 |
| Diluted shares | — | 1914M | 1920M | 1925M | 1931M | 1935M |
| Net debt | — | $18.57B | $11.16B | $3.11B | $-5.68B | $-15.25B |
| P/S multiple | — | 3.0x | 3.0x | 3.0x | 3.0x | 3.0x |
| Implied price (base) | — | $83.10 | $92.80 | $105.12 | $119.14 | $134.24 |
★ 2030E is the model's terminal target year. Implied price = (Revenue × P/S − Net debt) ÷ Diluted shares.
Scenario detail · Three drivers, three outcomes
| 2030E driver | Bear | Base | Bull |
|---|---|---|---|
| Revenue | $81.5B | $81.5B | $81.5B |
| P/S multiple | 1.0x | 3.0x | 5.0x |
| Diluted shares | 1935M | 1935M | 1935M |
| Net debt | $-15.25B | $-15.25B | $-15.25B |
| Implied P/E † | 3x | 9x | 14x |
| 2030 Price | $50.00 | $134.24 | $218.48 |
| NPV @ 7% | $36.29 | $97.43 | $158.57 |
† Implied P/E: Multiples remain elevated across all three scenarios because NVS is valued primarily on revenue scale during its growth phase, not near-term earnings power. Lower P/E in the bear case reflects multiple compression, but the absolute level stays high since 2030E still represents a hypergrowth-to-mature transition year.
EV to per-share bridge · How we get to $134.24 base case
NVS catalysts and risks
Growth catalysts
+ Radioligand therapy (RLT) facility ramp: 7th US manufacturing facility in Morrisville, NC and Denton, TX facility (operational by 2028) targeting personalized cancer therapies with significant gross margin profile
+ Pipeline expansion: $12B Avidity Biosciences deal, $3B Synnovation breast cancer drug acquisition, $2B Excellergy anti-IgE therapy (Xolair successor) — targeting high-growth oncology and allergy markets
+ Obesity/metabolic disease candidates: pipeline progress in weight-loss segment, positioning Novartis in multi-hundred-billion TAM with expanding competitor set but significant first-mover advantage in combination therapies
+ Recent FDA approvals: Beovu for diabetic macular edema, Cosentyx for pediatric hidradenitis suppurativa, Itvisma (SMA gene therapy) EU approval — expanding addressable markets in ophthalmology and rare disease
+ US market momentum: $23B domestic investment signals commitment to US manufacturing, supply chain resilience, and regulatory/pricing alignment with Trump administration pressures
Key risks
- US drug pricing pressure: Trump administration's drug price negotiation policies pose margin compression risk; Medicare price negotiations (Inflation Reduction Act) could impact blockbuster revenues (Cosentyx, Ziltivekimab, etc.)
- Patent cliffs: Sandoz generics spinoff and upcoming patent expirations in core franchises create revenue headwinds; legacy revenue base faces structural decline requiring pipeline execution
- Execution risk on pipeline: $3-12B in recent acquisitions (Avidity, Synnovation, Excellergy) must deliver clinical and commercial success; obesity market increasingly crowded with Novo Nordisk, Eli Lilly, Viking Therapeutics competition
- FX and macro headwinds: CHF strength versus USD, European healthcare cost controls, and weakening emerging market demand could pressure reported revenue growth
- Analyst downgrades: Recent Goldman Sachs downgrade to Sell ($118 target), Zacks Q2 2026 EPS cut ($2.24 from $2.37), and Q1 2026 EPS miss ($1.99 vs $2.11 consensus) signal near-term sentiment deterioration
Methodology · Novartis AG ADR 2030 stock forecast model
Novartis AG ADR 2030 price target is calculated using WallStSmart's research model. Revenue projections are derived from analyst consensus across 16 Wall Street analysts, management guidance from the latest earnings call, and sector growth forecasts. The model is built on five core components:
| 1. Share dilution | Projected from per-ticker schedule of SBC + equity raise activity, compounding year by year (1% cumulative for NVS by 2030) |
| 2. Net debt | EV minus net debt yields equity value; debt projected from capex cycle trajectory ($-15.25B by 2030) |
| 3. Time value | NPV calculated using 7% WACC (CAPM: beta 0.487) |
| 4. Multiple framework | P/S compresses with scale: bear 1.0x / base 3.0x / bull 5.0x |
| 5. Scenario design | Bull/Base/Bear vary revenue, margin, shares, debt, and multiple independently |
WallStSmart research model · Not financial advice · Past performance is not indicative of future results · Last researched: May 20, 2026.
NVS price target FAQ
What is the NVS price target for 2030?
WallStSmart's Novartis AG ADR 2030 base case is $134.24 per share, with a bull case of $218.48 and bear case of $50.00. The NPV of the base case discounted to today at 7% WACC is $97.43.
How is the Novartis AG ADR 2030 stock forecast calculated?
The NVS 2030 projection multiplies projected revenue by a growth-adjusted P/S multiple to derive enterprise value, subtracts projected net debt to get equity value, then divides by diluted shares outstanding accounting for dilution from stock-based compensation and equity raises.
Why does the NVS price target account for dilution?
Novartis AG ADR is projected to grow diluted share count from 1908M to 1935M by 2030 (a 1% increase) through stock-based compensation and capital raises. Ignoring this would inflate the price target by approximately 1%.
What is the analyst consensus on NVS stock?
16 analysts cover NVS with an average 12-month price target of $141.20. The 2030 projection extends this framework with longer-horizon assumptions including dilution and time value of money.